Latest News and Press Releases

- Two oral presentations highlighting data from plazomicin Phase 3 EPIC and CARE clinical trials - - Eleven poster presentations highlighting plazomicin’s activity against MDR Enterobacteriaceae,...

SOUTH SAN FRANCISCO, Calif., May 25, 2017 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company discovering and developing innovative antibacterials addressing...

SOUTH SAN FRANCISCO, Calif., May 23, 2017 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company developing innovative antibacterials addressing multi-drug...

SOUTH SAN FRANCISCO, Calif., May 23, 2017 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company discovering and developing innovative antibacterials addressing...

-- Presented additional Phase 3 EPIC and CARE trial data highlighting the safety and efficacy of plazomicin during late-breaker session at ECCMID -- -- Plazomicin registration activities on track;...

The Bill & Melinda Gates Foundation is committing up to $20 million in grant funding and equity investment to further the development of an antibody platform and discovery of monoclonal antibody...

SOUTH SAN FRANCISCO, Calif., May 01, 2017 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company discovering and developing innovative antibacterials addressing...

-- Evaluation of EPIC Phase 3 data demonstrates sustained clinical cure with plazomicin compared to higher clinical relapse rate with meropenem -- -- 28-Day mortality benefit of plazomicin versus...

-- Late-breaking oral presentations to highlight data from plazomicin Phase 3 EPIC and CARE clinical trials -- -- Newly-released in vitro data demonstrates activity of plazomicin against a large...

SOUTH SAN FRANCISCO, Calif., March 30, 2017 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company developing novel antibacterials addressing multi-drug resistant...